Drug Response Testing and Repurposing Using Glioblastoma Organoid

Recruiting now

Conditions studied: Glioblastoma, Organoid

In brief

The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.

Key facts

Study ID

NCT06782984

Run by

Chungnam National University Hospital

People needed

150

Starts

2021-08-18

Expected to finish

2030-12-01

Last updated by the study team

2025-01-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• primary or recurrent glioblastoma
• patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
• sufficient tumor sample is available for organoid culture

You may not qualify if…

• patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
• failed to obtain MRI scan after CCRT
• patients refusal

Where it is running

• Chungnam National University Hospital — Daejeon, Chungcheongnam-do, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.